566156-01-2

Basic information

• Product Name: 2-Pyridineethanamine,alpha,alpha-dimethyl-(9CI)
• Synonyms: 2-Pyridineethanamine,alpha,alpha-dimethyl-(9CI);2-Methyl-1-(pyridin-2-yl)propan-2-aMine
• CAS NO: 566156-01-2
• Molecular Formula: C₉H₁₄N₂
• Molecular Weight: 150.22086
• Product Categories: PYRIDINE
• Mol File: 566156-01-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-Pyridineethanamine,alpha,alpha-dimethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridineethanamine,alpha,alpha-dimethyl-(9CI)(566156-01-2)
• EPA Substance Registry System: 2-Pyridineethanamine,alpha,alpha-dimethyl-(9CI)(566156-01-2)

Safety Data

• Hazardous Substances Data: 566156-01-2(Hazardous Substances Data)

Usage

Description

2-Pyridineethanamine, alpha, alpha-dimethyl-(9CI), also known as 2-Dimethylaminomethylpyridine, is a tertiary amine with the molecular formula C8H12N2. It is a colorless, highly flammable liquid with a strong odor and is classified as harmful if ingested or inhaled. This chemical compound is commonly used as a catalyst in various chemical reactions, including the production of pharmaceuticals and polymers.

Uses

Used in Pharmaceutical Industry:
2-Pyridineethanamine, alpha, alpha-dimethyl-(9CI) is used as a catalyst for the synthesis of various pharmaceutical compounds. Its ability to facilitate chemical reactions makes it a valuable component in the production of medications.
Used in Polymer Industry:
In the polymer industry, 2-Pyridineethanamine, alpha, alpha-dimethyl-(9CI) serves as a catalyst to accelerate the production of polymers. Its use in this sector contributes to the manufacturing of various types of plastics and materials with specific properties.
Safety Precautions:
Due to its highly flammable nature and potential harm if ingested or inhaled, 2-Pyridineethanamine, alpha, alpha-dimethyl-(9CI) should be handled with caution. Strict safety regulations must be followed to ensure the protection of individuals and the environment during its use and storage.

Upstream product

• 16193-48-9 2-methyl-1-(pyridin-2-yl)-propan-2-ol 

Downstream Products

• 1198117-11-1 2-(2-methyl-1-(pyridin-2-yl)propan-2-yl)-3-oxo-N-(4-(trifluoromethoxy)benzyl)isoindoline-1-carboxamide 
• 1265633-72-4 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(2-methyl-1-(pyridin-2-yl)propan-2-yl)-1H-pyrazole-3-carboxamide 

Relevant articles and documents

ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS

Compounds of formula I are claimed, wherein R1is hydrogen, C1_3alkyl, C1_3alkoxy, cyano, hydroxy or halo; wherein C1-3alkyl may optionally be substituted by one or more substituents independently selected from hydroxy, C1-3alkoxy orfluoro; and wherein Ci^alkoxy may optionally be substituted by one or more fluoro; m is 1 or 2; R2 and R3 is each and independently selected from hydrogen, Ci_4haloalkyl, C1_4haloalkoxy, halo, C1_4alkoxy, C1_4alkyl and C3_7cycloalkyloxy; and wherein said C3_7cycloalkyloxy may optionally be substituted by one or more fluoro; and whereas both R2 and R3 can not be hydrogen; Het is selected from any one of pyridinyl, pyrazinyl, isoxazolyl, pyrazolyl, indolyl, triazolyl and pyrimidinyl, wherein each such heteroaryl may optionally be substituted by one or more X4; X4 is halo, C1-3alkyl, C1-3alkyl0C1-3alkyl, -CH(CH3)-O-C(CH3)3,C1_4alkoxy, cyano, or hydroxyl, or Ci_2hydroxyalkyl;; and wherein said C1-3alkyl, C 1-3alkylOC1-3alkyl, -CH(CH3)-O-C(CH3)3, or C1_4alkoxy may each optionally be substituted by one or more fluoro; L1 is C1_4alkylene, which may optionally be fluorinated or hydroxylated; and L2 is C1-3alkylene; with the exception of the compounds: 2-[1-(1,5-dimethyl-lH-pyrazol-4-yl)ethyl]-5,7-dimethoxy-3-oxo-N-[2-(trifluoromethyl)benzyl]isoindoline-1-carboxamide; N-(4-fluorobenzyl)-3-oxo-2-(-pyridin-4-yletyl)isoindoline-1-carboxamide and N-(2-chlorobenzyl)-2[2-(1H-indol-3-yl)-1-methyletyl]-3-oxoisoindoline-1-carboxamide; The invention further relates to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.